The latest price target for Biomarin Pharmaceutical (NASDAQ:BMRN) was reported by Oppenheimer on February 24, 2025. The analyst firm set a price target for $98.00 expecting BMRN to rise to within 12 months (a possible 37.72% upside). 57 analyst firms have reported ratings in the last year.

The latest analyst rating for Biomarin Pharmaceutical (NASDAQ:BMRN) was provided by Oppenheimer, and Biomarin Pharmaceutical upgraded their outperform rating.

The last upgrade for Biomarin Pharmaceutical Inc happened on February 24, 2025 when Oppenheimer raised their price target to $98. Oppenheimer previously had a perform for Biomarin Pharmaceutical Inc.

The last downgrade for Biomarin Pharmaceutical Inc happened on October 30, 2024 when William Blair changed their price target from N/A to N/A for Biomarin Pharmaceutical Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on February 24, 2025 so you should expect the next rating to be made available sometime around February 24, 2026.

While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a upgraded with a price target of $0.00 to $98.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $71.16, which is within the analyst’s predicted range.